Abstract
Background Since gemcitabine became the standard treatment for metastatic pancreatic adenocarcinoma, combination chemotherapy obtained conflicting impact on survival (OS). Aims To evaluate Italian treatment trends in metastatic pancreatic cancer. Methods Data on treatment outcome of 943 chemo-naive patients with pathological diagnosis of stage IV pancreatic adenocarcinoma treated between 1997 and 2007 in Italian centres were analysed. Results Four treatment groups could be identified: (1) single agent gemcitabine ( N = 529); (2) gemcitabine–platinating agent doublets ( N = 105); (3) gemcitabine-free three-drug intraarterial combination ( N = 75); (4) four-drug gemcitabine–cisplatin–fluoropyrimidine based combinations ( N = 170). Median and actuarial 1 y OS of the whole population were 6.2 months and 20%, respectively. Gemcitabine (median OS 5.1 months) appeared significantly inferior to gemcitabine-free triplets (median OS 6.0 months; p = .04), gemcitabine–platinating agent doublets (median OS 7.4 months; p = .00001), or gemcitabine-based four drug combinations (median OS 9.1 months; p < .00001). Conclusion These data mirror the Italian clinical practice in the therapeutic management of pancreatic cancer and suggest that four-drug combination chemotherapy may be included amongst the candidate regimens for phase III testing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
